MedPath

To understand usage pattern, and effectiveness of sacubitril/valsartan in heart failure

Not Applicable
Conditions
Health Condition 1: I462- Cardiac arrest due to underlying cardiac condition
Registration Number
CTRI/2023/10/058403
Lead Sponsor
Dr Reddys Laboratories Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Heart failure Patients who have been prescribed with CIDMUS and ejection fraction (EF) value are reported at baseline.

2.Patients of either sex =18 years of age

Exclusion Criteria

Patients for whom EF value is not reported at baseline

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. To evaluate the usage of sacubitril/valsartan across different <br/ ><br>ranges of EF (=40%, 41-49%, =50%) – signifying HF with <br/ ><br>reduced EF (HFrEF), HF with moderately reduced EF <br/ ><br>(HFmrEF), & HF with preserved EF (HFpEF), respectively. <br/ ><br> <br/ ><br>2.To understand baseline demographics – patients’ age, gender, <br/ ><br>body mass index (BMI), systolic blood pressure (SBP), <br/ ><br>diastolic blood pressure (DBP), comorbid conditions and <br/ ><br>concomitant medications like beta blocker [BB], <br/ ><br>mineralocorticoid receptor antagonist [MRA], Sodium-glucose cotransporter-2 [SGLT2] inhibitors and <br/ ><br>combinations) as monotherapy and/or combination therapy in <br/ ><br>HF patients on sacubitril/valsartan.Timepoint: 2017 to 2023 <br/ ><br>(Data will be captured for one consecutive follow-up visit from the baseline visit/index <br/ ><br>date)
Secondary Outcome Measures
NameTimeMethod
•The effect of CIDMUS on change in EF from baseline <br/ ><br>•Change in SBP, & DBP from baseline to follow up visits <br/ ><br>•Change in potassium levels from baseline to follow up visit <br/ ><br>•Average dose & dose titrations of CIDMUS <br/ ><br>Timepoint: 2017 to 2023 <br/ ><br>(Data will be captured for one consecutive follow-up visit from the baseline visit/index <br/ ><br>date)
© Copyright 2025. All Rights Reserved by MedPath